However, for patients with complex metabolic needs, such as those at risk for non-alcoholic fatty liver disease (NAFLD) or dyslipidaemia, Retatrutide could be a valuable option - especially as future long-term studies may reveal additional benefits from glucagon receptor activation. This evidence concerns the gene GCGR and inherited lipid metabolism disorder.